Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HL08
- Development stage
- Unknown
- Lead developer
- Hualan Biological Engineering
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
HL08 is a biosimilar candidate of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Hualan Biological Engineering for the treatment of type 2 diabetes mellitus. As a synthetic version of exendin-4, it mimics the action of endogenous GLP-1 by binding to and activating the GLP-1 receptor. This activation enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion, and slows gastric emptying, thereby improving glycemic control. HL08 is designed to provide a therapeutic alternative to the reference product, Byetta, and is typically administered via subcutaneous injection.
- Other names
- exenatide biosimilarHualan exenatide
02
Targets
Beyond the preview
Go deeper on HL08.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HL08.